3933 On Other Exchanges
Symbol
Exchange
3933 is not on other exchanges.

the united laboratories inte (3933) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THE UNITED LABORATORIES INTE (3933)

Related News

No related news articles were found.

the united laboratories inte (3933) Related Businessweek News

No Related Businessweek News Found

the united laboratories inte (3933) Details

The United Laboratories International Holdings Limited, an investment holding company, manufactures and sells pharmaceutical products. It operates in three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers antibiotic and non-antibiotic finished products, and soft capsules casings. It also produces and sells bulk medicine, pharmaceutical intermediate products, and organic fertilizers. In addition, the company engages in trading pharmaceutical products. It operates primarily in the People's Republic of China, Europe, India, Hong Kong, the Middle East, South America, other Asian regions, and other regions. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited operates as a subsidiary of Choy Family Trust.

11,300 Employees
Last Reported Date: 09/27/16
Founded in 1990

the united laboratories inte (3933) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $3.8M
Vice Chairman, Chief Financial Officer and Co...
Total Annual Compensation: $3.7M
Vice President, General Manager of China Sale...
Total Annual Compensation: $2.7M
Vice President and Executive Director
Total Annual Compensation: $2.7M
Vice President and Executive Director
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2015.
the united laboratories inte
China State Food and Drug Administration Approves The United Laboratories International Holdings Limited's Insulin Glargin Bulk Medicine and Insulin Glargin Finished Product

The board of directors of The United Laboratories International Holdings Limited announced that it was informed by China State Food and Drug Administration that the applications of the Group's insulin glargin bulk medicine and insulin glargin finished product have been approved with approval number of S20160010 and S20160009 respectively. The approved insulin glargin product is the specification of refilled pen-type injection. It is expected that the relevant insulin products will be launched to the market soon. Insulin glargin is a long-acting insulin analog of the third generation insulin products. In addition, the Group's four recombinant human insulin finished products of the second generation insulin (including the four specifications: N, R, 30R and 50R) have been launched to the market in 2011. After the approval of insulin glargin, the Group is the pharmaceutical enterprise of the second and third generation insulin products in China. Apart from the products mentioned above, the Group's insulin products in R&D also cover insulin aspart, insulin detemir, insulin degludec, etc. It is expected that the above products will be launched to the market gradually so that the Group's insulin pipeline will be enriched and will bring considerable return to the company and its shareholders in future.

The United Laboratories International Holdings Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016

The United Laboratories International Holdings Limited announced unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, the company's net cash from operating activities was HKD 255,283,000 against HKD 1,118,516,000 a year ago. Payments for purchase of property, plant and equipment were HKD 107,381,000 against HKD 377,723,000 a year ago. Additions to intangible assets were HKD 26,230,000 against HKD 27,404,000 a year ago.

The United Laboratories International Holdings Limited Announces Unaudited Consolidated Earnings Results for the Half Year Ended June 30, 2016

The United Laboratories International Holdings Limited announced unaudited consolidated earnings results for the half year ended June 30, 2016. For the period, the company reported turnover of HKD 3,503,506,000 against HKD 4,062,365,000 a year ago. Profit before taxation was HKD 100,336,000 against HKD 259,380,000 a year ago. Loss for the year attributable to owners of the company was HKD 15,107,000 or 0.93 cents per basic and diluted share against profit of HKD 280,279,000 or 17.23 cents per basic and diluted share a year ago. EBITDA was HKD 661,194,000 against HKD 803,364,000 a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

3933 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3933.
View Industry Companies
 

Industry Analysis

3933

Industry Average

Valuation 3933 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact THE UNITED LABORATORIES INTE, please visit www.tul.com.cn. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.